Research Highlights

UB Department of Neurology research scientists and physician-scientists have made important and internationally recognized contributions to medical science, including patents, discoveries and treatment advances.

The drug most prescribed to people with relapsing multiple sclerosis.

The University at Buffalo has officially launched the UB Biorepository, a critical new facility in the Clinical and Translational Research Center that will serve as a powerful resource in driving biomedical innovation in academia and industry regionally and throughout the state.


The National Multiple Sclerosis Society (NMSS) has funded two separate projects led by researchers in the departments of Neurology and Pharmacology and Toxicology.


Building on a successful pilot study, Thomas J. Guttuso Jr., MD, associate professor of neurology and obstetrics and gynecology, will test the effectiveness of the anticonvulsant drug gabapentin in treating hyperemesis gravidarum, a rare but disabling condition of early pregnancy.

Dementia and Alzheimer’s disease may be related to a vascular abnormality in the internal jugular veins, according to a revealing pilot study by an international research team, including University at Buffalo scientists.

UB researchers and their global collaborators are building a growing body of evidence that links changes in the brain’s thalamus region to MS.


Research at UB’s Hunter James Kelly Research Institute has provided proof of principle for how a genetic mutation leads to some neuropathies.


UB researchers found that aerobic exercise may help restore normal cognitive function in patients who have suffered a concussion.

Balloon angioplasty does not improve outcomes for patients with multiple sclerosis—and, in a few cases, worsened symptoms, according to a landmark UB clinical trial.